Abstract
The accumulation of amyloid-β protein (Aβ) is an early event associated with synaptic and mitochondrial damage in Alzheimer’s disease (AD). Recent studies have implicated the filamentous actin (F-actin) severing protein, Cofilin, in synaptic remodeling, mitochondrial dysfunction, and AD pathogenesis. However, whether Cofilin is an essential component of the AD pathogenic process and how Aβ im**es its signals to Cofilin from the neuronal surface are unknown. In this study, we found that Aβ42 oligomers (Aβ42O, amyloid-β protein 1–42 oligomers) bind with high affinity to low or intermediate activation conformers of β1-integrin, resulting in the loss of surface β1-integrin and activation of Cofilin via Slingshot homology-1 (SSH1) activation. Specifically, conditional loss of β1-integrin prevented Aβ42O-induced Cofilin activation, and allosteric modulation or activation of β1-integrin significantly reduced Aβ42O binding to neurons while blocking Aβ42O-induced reactive oxygen species (ROS) production, mitochondrial dysfunction, depletion of F-actin/focal Vinculin, and apoptosis. Cofilin, in turn, was required for Aβ42O-induced loss of cell surface β1-integrin, disruption of F-actin/focal Talin–Vinculin, and depletion of F-actin-associated postsynaptic proteins. SSH1 reduction, which mitigated Cofilin activation, prevented Aβ42O-induced mitochondrial Cofilin translocation and apoptosis, while AD brain mitochondria contained significantly increased activated/oxidized Cofilin. In mechanistic support in vivo, AD mouse model (APP (amyloid precursor protein)/PS1) brains contained increased SSH1/Cofilin and decreased SSH1/14-3-3 complexes, indicative of SSH1–Cofilin activation via release of SSH1 from 14-3-3. Finally, genetic reduction in Cofilin rescued APP/Aβ-induced synaptic protein loss and gliosis in vivo as well as deficits in long-term potentiation (LTP) and contextual memory in APP/PS1 mice. These novel findings therefore implicate the essential involvement of the β1-integrin–SSH1–Cofilin pathway in mitochondrial and synaptic dysfunction in AD.
Similar content being viewed by others
Main
The defining pathological hallmark of Alzheimer’s disease (AD) is the accumulation of amyloid-β protein (Aβ) in brain associated with tau pathology, synapse loss, cytoskeletal aberrations, mitochondrial dysfunction, and cognitive decline. Soluble oligomeric forms of Aβ are thought to be the most toxic species, resulting in synaptic loss and downstream neurotoxicity.1 An early and consistent impairment secondary to Aβ oligomer treatment in primary neurons is the shrinkage of dendritic spines2 involving the rearrangement of filamentous actin (F-actin) cytoskeleton in spines and loss of spine-associated proteins such as postsynaptic density-95 (PSD95) and Drebrin,3, 4 as well as impaired mitochondrial function.5, 6 Studies have implicated an involvement of the F-actin-severing protein Cofilin in Aβ-induced dendritic spine changes,3, 4 accumulation of Cofilin–Actin aggregates/rods in AD brains,7 and increased Cofilin activity in brains of AD patients.8 Cofilin normally functions as a key regulator of Actin dynamics that destabilizes F-actin. Cofilin is inactivated by phosphorylation on Ser3 by LIM kinase 1 (LIMK1), whereas its dephosphorylation by Slingshot homology-1 (SSH1) activates Cofilin.9, 10, 11 Upon oxidative stress and/or Ca2+ elevation,9, 12, 13 SSH1 is activated and active Cofilin becomes oxidized on cysteine residues, resulting in rapid mitochondrial translocation to promote mitochondria-mediated apoptosis and induction of Cofilin–Actin pathology.14, 15 Despite the circumstantial evidence for the involvement of Cofilin in AD pathogenesis, no direct evidence thus far has been presented.
Heterodimeric integrins (α- and β-subunits) comprise major adhesion receptors that regulate multiple facets of cellular function, including adhesion, motility, survival, and synaptic plasticity.16 A primary function of integrins is to link the extracellular matrix to the F-actin cytoskeleton via structural scaffolding proteins such as Talin and Vinculin.17, 18 Among several proposed surface Aβ oligomer receptors such as PrPc (Prion protein (cellular))/mGluR5 (metabotropic glutamate receptor 5)19, 20 and paired immunoglobin-like receptor-B (Pir-B)8, it has been shown that α2/β1 and αv/β1-integrins are also required to mediate Aβ-induced apoptosis and impairment in LTP.21, 22 However, whether Aβ binds directly to integrins and how Aβ engagement alters downstream integrin function are unknown. In this study, we explored the mechanistic relationships among Aβ42O (amyloid-β protein 1–42 oligomers), β1-integrin, and Cofilin activities in vitro, HT22 cells, primary neurons, and genetically modified mice. Here we show that Aβ42O exhibits direct high-affinity binding β1-integrin, inducing its conformational alteration, loss of surface β1-integrin, and disruption of integrin-associated focal complexes (FCs), as well as mitochondrial and synaptic dysfunction via a pathway involving ROS-dependent activation of SSH1 and Cofilin.
Results
Aβ42O induces loss of cell surface β1-integrin but not TfR or PrPc and reduces β1-integrin activation
We prepared Aβ1-42 oligomers (Aβ42O) as previously characterized.23 These Aβ42O preparations contained SDS-resistant dimers, trimers, and tetramers (Supplementary Figure S1A). The indicated Aβ42O concentrations, heretofore, are based on the monomer concentration. To determine whether Aβ42O alters surface levels or activation status of β1-integrin, we plated the hippocampus-derived HT22 mouse cell line in the presence and absence of fibronectin (FN) coating, treated them with Aβ42O for 2 h and performed cell surface biotinylation experiments. Cell surface β1-integrin normalized to total was significantly reduced by ~60% regardless of FN coating after Aβ42O treatment without altering total β1-integrin, although FN coating also significantly increased surface β1-integrin (Figures 1a and b; and Supplementary Figures S1B and C). Although FN coating modestly, but significantly, increased surface/total transferrin receptor (TfR), Aβ42O (1 μM) had no significant effect on surface TfR (Figures 1a and c). Surface PrPc was unaffected by either FN coating or Aβ42O treatment (Figures 1a and d). In FN-coated coverslips, Aβ42O (2 h) also significantly reduced total surface β1-integrin levels by ~45% and further reduced activated surface β1-integrin by ~75% as detected by the HUTS-4 antibody24 in non-permeabilized cells (Figures 1e and f). In days in vitro (DIV)-14 fixed and permeabilized neurons, Aβ42O treatment per se significantly reduced the FITC (fluorescein isothiocyanate)-HUTS-4-positive activated β1-integrin by >50%, which was significantly prevented by the β1-integrin allosteric modulating antibody (MAB1965)25 and the PrPc function blocking antibody (6D11)19 (Figures 1g and h).
Aβ42O induces loss of cell surface β1-integrin but not TfR or PrPc and reduces β1-integrin activation. (a–d) HT22 cells plated with/without FN, treated with/without Aβ42O (1 μM, 2 h), subjected to surface biotinylation (surface), and direct immunoblotting (total) or immunoprecipitation for biotin (surface) and immunoblotting for the indicated proteins. (b–d) Quantification of normalized surface/total β1, TfR, and PrPc (n⩾3 replicates, ANOVA, post hoc Tukey,*P<0.05, #P<0.0005). Error bar represent S.E.M. (e and f) HT22 cells treated with /without Aβ42O and immunostained for total surface β1-integrin or activated surface β1-integrin (HUTS-4 antibody) without membrane permeabilization (n⩾4 replicates, T-test, **P<0.005, #P<0.0005). (g and h) Direct staining for activated β1-integrin (FITC-HUTS-4 antibody) in fixed and permeabilized DIV14 primary hippocampal neurons after treatment with/without Aβ42O (1 μM, 2 h) and/or control ascites IgG (1 : 250), MAB1965 (1 : 250), or 6D11 (1 : 50). (h) Quantification of FITC-HUTS-4 immunoreactivity (n=4 replicates, ANOVA, post hoc Tukey,*P<0.05, **P<0.005)
β1-integrin allosteric modulation or activation reduces Aβ42O binding to neurons, HT22 cells, and purified β1-integrin
We next assessed Aβ42O binding to mature DIV21 hippocampal neurons by adding 100 nM FITC-Aβ42O for 1 h at 37 °C with prior incubation (1 h) with control immunoglobulin G (IgG), MAB1965, or HUTS-4 monoclonal IgGs. As expected, FITC-Aβ42O associated with dendrites and dendritic spines, and such binding was significantly reduced by MAB1965 IgG by ~50% (Figures 2a and b). The HUTS-4 IgG, which has been shown to enhance ligand binding to β1-integrin,26 also significantly reduced FITC-Aβ42O binding to neurons by >60% (Figures 2a and b). As previously shown,19 6D11 IgG significantly reduced FITC-Aβ42O binding to neurons by ~50% (Figures 2a and b). In β1-integrin fl/fl neurons (conditional knockout, cKO)27 transduced with high-titer lentiviruses expressing Cre-monomeric red fluorescent protein (mRFP), FITC-Aβ42O binding to neurons was significantly reduced by >60% (Figures 2c and d) while reducing β1-integrin expression by ~80–90% (Figure 2e). We next determined whether Aβ binds directly to β1-integrin-Fc (extracellular domain fused with human IgG-Fc).26 Biotin-Aβ42O bound to purified β1-integrin-Fc (Figure 2f) coated on ELISA plates with high affinity in the presence of 5 mM MgCl2, which induces an intermediate open integrin conformation (Figure 2g; Kd=11.3 nM based on monomer calculation). In the absence of cation, minimal binding of Aβ42O to β1-integrin-Fc was detected and did not appreciably increase with increasing biotin-Aβ42O (Figure 2g). Surprisingly, MnCl2 (0.5 mM), which induces the maximal open activation state of integrins,26 failed to support Aβ42O binding to β1-integrin-Fc (Figure 2g), indicating that Aβ42O prefers an intermediate activation state of β1-integrin. Accordingly, FITC-Aβ42O binding to HT22 cells was also significantly reduced in the presence of 0.5 mM MnCl2 or MAB1965 but not MgCl2 (Figures 2h and i). Unlike Aβ42O, Aβ42 monomers and fibrils bound poorly to β1-integrin-Fc (Supplementary Figure S2).
β1-Integrin allosteric modulation or activation reduces Aβ42O binding to neurons, HT22 cells, and purified β1-integrin as effectively as the loss of β1-integrin (a and b) FITC-Aβ42O (100 nM, 1 h) binding to DIV21 primary hippocampal neurons with/without prior treatment (1 h) of control IgG, MAB1965 (β1-integrin allosteric modulator, 1 : 250), HUTS-4 (β1-integrin allosteric activator, 1 : 250), and/or 6D11 (PrPc blocking, 1 : 50) monoclonal antibodies. Bottom panel magnified from regions of white rectangles. (b) Quantification of FITC-Aβ42O binding (n⩾5 replicates, ANOVA, post hoc Tukey, #P<0.0005 compared with control IgG). Error bars represent S.E.M. (c–e) FITC-Aβ42O (100 nM, 1 h) binding to β1-integrin fl/fl neurons transduced with Lenti-mRFP (cont) or Lenti-Cre-mRFP (β1 cKO). (d) Quantification of FITC-Aβ42O binding (n=5 replicates, T-test, #P<0.0005). (e) Representative blots of β1-integrin from cKO (Lenti-Cre-mRFP) versus cont (Lenti-mRFP) neurons (all neurons including nontransduced). (f) Conditioned medium from CHO cells transfected with β1-integrin-Fc affinity purified with anti-Fc affinity column, sequentially eluted, and immunoblotted with anti-Fc. (g) Purified β1-integrin-Fc from fractions 1 and 2 captured by 96-well plates coated with anti-Fc IgG, subjected to biotin-Aβ42O binding and/or incubated with different cations (MgCl2, 5 mM and MnCl2, 0.5 mM). (h) Kd=10.3 nM with MgCl2. Two-way ANOVA post hoc Bonferroni, n=4 replicates, #P<0.0005. (h and i) HT22 cells treated with FITC-Aβ42O (0.1 μM, 2 h) and/or β1-integrin blocking IgG (MAB1965, 1 : 500), MnCl2 (0.5 mM), or MgCl2 (5 mM), and subjected fluorescence microscopy. (h) Representative images of FITC-Aβ42O binding/uptake show inhibition by MAB1965 antibody and MnCl2. (i) Quantification of mean intensities of FITC-Aβ42O binding/uptake (n=4 replicates, ANOVA, post hoc Tukey, **P<0.005 compared with FITC-Aβ42O alone)
Essential role of β1-integrin in Aβ42O-induced cofilin activation and reciprocal requirement of cofilin in Aβ42O-induced depletion of surface β1-integrin and FCs
Aβ42O (2 h, 1 μM) treatment to primary cortical neurons significantly induced Cofilin dephosphorylation/activation (Figures 3a and b). However, such Cofilin dephosphorylation was absent in β1-integrin cKO neurons transduced with Lenti-Cre-mRFP (Figures 2a and b). We next determined whether Cofilin per se is also required for the observed Aβ42O-induced depletion of cell surface β1-integrin in HT22 cells. Aβ42O reduced surface β1-integrin, and Cofilin siRNA reduced Cofilin levels (Figure 3c). However, Cofilin siRNA increased surface β1-integrin levels and prevented the Aβ42O-induced reduction in surface β1-integrin (Figure 3c). Quantification of surface β1-integrin and PrPc levels secondary to Cofilin siRNA demonstrated that Cofilin knockdown significantly increases the surface/total β1-integrin ratio without affecting surface/total PrPc ratio (Figures 3d and e), similar to that observed with Aβ42O treatment.
Essential role of β1-integrin in Aβ42O-induced Cofilin activation as well as reciprocal requirement of Cofilin in Aβ42O-induced depletion of surface β1-integrin and F-actin-associated FCs (Vinculin and Talin). (a and b) DIV14 cortical WT or β1-integrin cKO neurons (transduced with Lenti-Cre) treated with/without Aβ42O (1 μM, 2 h) and subjected to immunoblotting. Note the decrease in p-Cofilin by Aβ42O in WT but not in β1 cKO neurons (n=4 replicates, T-test, *P<0.05). Error bars represent S.E.M. (c) HT22 cells transfected with control or Cofilin siRNA, treated with Aβ42o (1 μM, 2 h) and subjected cell surface biotinylation followed by direct immunoblotting or IP with anti-biotin and immunoblotting. Note that Cofilin knockdown prevents Aβ42O-induced depletion of surface β1-integrin. (d and e) HT22 cells transfected with control or Cofilin siRNA and subjected to cell surface biotinylation followed by direct immunoblotting or IP with anti-biotin and immunoblotting. (d) A representative experiment showing a dramatic increase in surface β1-integrin but no change in surface PrPc after Cofilin knockdown. (e) Quantification of β1-integrin normalized to total β1-integrin and surface PrPc normalized to total PrPc (n=4 replicates, T-test, #P<0.0005). (f and g) DIV21 hippocampal primary neurons treated with/without Aβ42O (1 μM, 2 h) and subjected to staining for Vinculin, F-actin (rhodamine-phalloidin), and DAPI. Note the near complete co-localization of Vinculin with F-actin, particularly in dendritic spines and loss of Vinculin immunoreactivity with Aβ42O treatment. (g) Quantification of focal Vinculin mean intensity (FC Vinculin) in dendrites and dendritic spines after subtracting the mean diffuse cytosolic intensity in dendrites (n=5 replicates, T-test, #P<0.0005). Error bars represent S.E.M. (h and i) DIV14 cortical WT and Cofilin+/− neurons treated with/without Aβ42O (1 μM), subjected to separation of cytosol and FC-enriched fractions followed by immunoblotting. (h) Representative blots showing Aβ42O-induced depletion FC Vinculin and Talin in WT but not in Cofilin+/− neurons. (i) Quantification of FC Vinculin and Talin after 2 h Aβ42O treatment normalized to respective vehicle treated controls at 100%. (n=3 replicates, T-test, *P<0.05, **P<0.01). (j and k) Eight-month-old APP/PS1 transgenic mice and their nontransgenic littermates (WT) stereotaxically injected with 2 μl β1-integrin blocking antibody (MAB1965, diluted 1 : 10) into the left hippocampus and 2 μl control IgG (control ascites fluid, diluted 1 : 10) into the right hippocampus and subjected to immunohistochemistry for Vinculin 48 h post injection. (j) Representative images of Vinculin FCs (red) in the CA3 of the hemisphere injected with β1-integrin blocking antibody compared with the control IgG injected contralateral hemisphere. Focal Vinculin threshold adjusted to convert highest intensity signals from green to red puncta without altering diffuse cytosolic signal. (k) Quantification of focal Vinculin area and size normalized to control IgG (n=5 mice, 2 M and 3 F, T-test, **P<0.005)
A direct consequence of β1-integrin internalization is the disruption of integrin and F-actin-associated FCs, structurally organized by Talin and Vinculin. We treated DIV14 cortical neurons or HT22 cells with or without Aβ42O (1 μM) and subjected them to sequential extraction of the cytosolic fraction on ice with the surfactant saponin, followed by extraction of membrane and cytoskeletal elements with SDS sample buffer (FC-enriched fraction). Aβ42O saliently reduced FC-enriched but not cytosolic (cyto) Vinculin and Talin in primary neurons (Supplementary Figure S3A) and HT22 cells (Supplementary Figures S3B and C). To observe focal Vinculin in a different way, we cultured primary hippocampal neurons to DIV21 and treated them with or without Aβ42O for 2 h followed by staining for Vinculin and F-actin. Regardless of Aβ42O treatment, Vinculin nearly completely co-localized with F-actin, and discrete puncta positive for both Vinculin and F-actin were seen in dendritic spines (Figure 3f). However, Aβ42O exposure significantly reduced focal Vinculin immunoreactivity in spine-containing dendrites after subtracting the diffuse cytosolic stain in dendrites (Figures 3f and g). In 7-month wild-type (WT) mice, Vinculin immunoreactivity in the CA3 pyramidal neurons demonstrated punctate immunoreactivity throughout neuronal cell bodies, indicative of FCs, with little diffuse staining. However, in 7-month-old APP/PS1 transgenic littermates,28 Vinculin immunoreactivity appeared markedly more diffuse and cytosolic in the CA3 pyramidal neurons (Supplementary Figure S3D), with significant 75% and ~50% reductions in area and size of focal Vinculin, respectively, in APP/PS1 mice compared with WT littermates (Supplementary Figure S3E).
Aβ42O treatment (1 μM) to WT neurons depleted focal Vinculin and Talin (Figure 3h). However, the same treatment in littermate Cofilin+/− neurons did not significantly deplete Vinculin and Talin in the FC-enriched fraction compared with WT neurons (Figures 3h and i). Accordingly, Cofilin knockdown also prevented Aβ42O-induced depletion of focal Vinculin in HT22 cells (Supplementary Figures S4A and B). Next, we stereotaxically injected 8-month-old APP/PS1 mice hippocampi with 2 μl β1-integrin allosteric modulating/neutralizing antibody (MAB1965 prediluted 1 : 10) into the right hemisphere and control IgG (control ascites fluid prediluted 1 : 10) into the left hemisphere. Forty-eight hours post injection, MAB1965 IgG significantly increased focal Vinculin area and size in CA3 pyramidal neurons compared with control IgG in the contralateral hemisphere (Figures 3j and k), indicating that endogenous β1-integrin mediates APP/Aβ-induced depletion of focal Vinculin in brain.
Essential roles of cofilin and β1-integrin in Aβ42O-induced depletion of F-actin and F-actin-associated synaptic proteins in primary hippocampal neurons
The primary function of Cofilin is to sever F-actin, which promotes synaptic remodeling via accelerating Actin dynamics.29 As Aβ42O induced Cofilin activation, we cultured hippocampal neurons derived from Cofilin+/− and WT littermate mice and cultured them to DIV21. Aβ42O (1 μM, 2 h) significantly depleted F-actin, Drebrin, and PSD95 in dendritic spines and spine-containing neurites of WT neurons (Figures 4a and b). However, the same Aβ42O treatment had no significant effects in Cofilin+/− neurons (Figures 4a and b), indicating that a critical threshold of endogenous Cofilin is required for Aβ42O-induced depletion of F-actin, Drebrin, and PSD95. Likewise, allosteric modulation of β1-integrin with MAB1965 IgG completely prevented the depletion of F-actin and PSD95 induced by Aβ42O (Figures 4c and d), indicating that the β1-integrin-Cofilin pathway mediates Aβ42O-induced changes in F-actin and F-actin-associated postsynaptic proteins.
Essential roles of Cofilin and β1-integrin in Aβ42O-induced depletion of F-actin and associated synaptic proteins in primary hippocampal neurons. (a and b) WT and Cofilin+/− DIV21 hippocampal neurons treated with/without Aβ42O (1 μM, 2 h) and stained for F-actin (rhodamine-phalloidin), Drebrin, or PSD95. (b) Quantification of mean intensities of Drebrin, PSD95, and F-actin in spine-containing neurites (n=4–6 replicates, ANOVA, post hoc Tukey, *P<0.05, **P<0.005, #P<0.0005). Error bars represent S.E.M. (c and d) DIV21 hippocampal neurons treated with/without Aβ42O (1 μM, 2 h) and/or control IgG or β1-integrin IgG (MAB1965) and stained for PSD95 and F-actin (rhodamine-phalloidin). (c) Representative images showing depletion of PSD95 and F-actin after Aβ42O treatment, which is prevented by MAB1965. (d) Quantification of mean PSD95 and F-actin intensities in spine-containing neurites (n⩾6 replicates, ANOVA, post hoc Tukey, *P<0.05, **P<0.005)
Requirement of SSH1 in Aβ42O-induced cofilin translocation to mitochondria and accumulation of mitochondrial cofilin in AD brains
Activated and oxidized Cofilin is known to translocate to mitochondria, where it induces mitochondrial dysfunction.13, 14 We treated HT22 cells with or without Aβ42O (1 μM) for 0, 2, and 4 h and fractionated intact mitochondria from cytosol. Aβ42O rapidly increased the translocation of Cofilin to mitochondria, while decreasing phospho-Cofilin in the cytosol (Figures 5a and b). No phospho-Cofilin was detected in the mitochondrial fraction (Figure 5a), consistent with its activation requirement for translocation. RNAi-mediated knockdown of SSH1, the phosphatase that activates Cofilin,10 significantly prevented Aβ42O-induced translocation of Cofilin to mitochondria together with increased Cofilin phosphorylation (Figure 5c), indicating that Aβ42O activates and promotes Cofilin translocation to mitochondria via SSH1. We next isolated mitochondria from the frontal cortex of age-matched cognitively normal control and AD patients (Supplementary Figure S5). In the absence of DTT in sample buffer (non-reducing), we detected cysteine-oxidized Cofilin monomers, dimers, trimers, and higher-order oligomers, which essentially all collapsed to the monomer form in the presence of DTT (reducing; Figure 5d). This banding pattern is similar to that observed from Cofilin–Actin rods, which also require activation and oxidation-induced disulfide bonding to form.15 Total Cofilin (all four bands in non-reducing condition), oxidized Cofilin oligomers (dimers or larger), and Cofilin monomers were significantly increased in mitochondria of AD (Figures 4d and e), results that fulfill the prediction from cultured cells, and suggest that activated and oxidized mitochondrial Cofilin has a pathogenic role in AD.
Requirement of Slingshot-1 (SSH1) in Aβ42O-induced Cofilin translocation to mitochondria and accumulation of mitochondrial Cofilin in AD brains. (a and b) HT22 cells treated with/without Aβ42O (1 μM) for the indicated times and subjected to separation of mitochondria and cytosol fractions followed by immunoblotting for the indicated proteins. (a) Representative blots showing Cofilin dephosphorylation (cytosol) and translocation to mitochondria (mito) after Aβ42O treatment. (b) Quantification of cytosolic and mitochondrial Cofilin (n=4 replicates, T-test, **P<0.005, #P<0.0005). (c) HT22 cells transfected with control or SSH1 siRNA, treated with/without Aβ42O (1 μM, 4 h), and subjected to separation of cytosol versus mitochondria followed by immunoblotting for the indicated proteins. Note that SSH1 siRNA prevents Aβ42O-induced Cofilin dephosphorylation and translocation to mitochondria (n=4 replicates, ANOVA, post hoc Tukey, #P<0.0005). (d and e) Mitochondria isolated from mid-frontal cortex of AD (n=5) and cognitively NC (n=4) and immunoblotted for Cofilin and Timm50 with or without DTT in sample buffer. (d) Representative blots showing abundance of Cofilin monomers (CofM), dimers (CofDi), trimers (CofTri), and high molecular weight species (CofH) in AD (blot on left run without DTT). Samples with asterisk (*) run with DTT and boiling show reduction of oxidized Cofilin oligomers to collapsed monomers (blot on right). (e) Quantification of Cofilin total (all four Cofilin bands), oligomers (CofDi, CofTri, and CofH), and monomers (CofM) (T-test, *P<0.03)
Aβ42O-induced ROS production, mitochondrial dysfunction, and apoptosis via the β1-integrin–SSH1–Cofilin activation pathway
HT22 cells were treated with Aβ42O (1 μM) with or without vehicle, NADPH oxidase (NOX) inhibitor, HUTS-4 IgG, or MAB1965 IgG and then subjected to live-cell imaging for JC-1, Mitosox-Red, and H2DCF (2′,7′-dichlorofluorescein). As expected, Aβ42O treatment (1 μM, 2 h) significantly decreased mitochondrial membrane potential (increased JC-1 green/red ratio), increased mitochondrial superoxide (Mitosox-Red), and increased ROS levels (H2DCF; Figures 6a and b; and Supplementary Figure S6A). However, co-incubation with HUTS-4, MAB1965, or NOX inhibitor significantly prevented such changes induced by Aβ42O, although the JC-1 membrane potential measure was not fully restored by these treatments (Figures 6a and b and Supplementary Figure S6A). Accordingly, MAB1965 significantly prevented Aβ42O-induced apoptosis in primary neurons and HT22 cells as assessed by Annexin V/PI staining (Supplementary Figures S6B and D). Similarly, Annexin V/PI staining also demonstrated significant induction of early (Annexin V) and late (PI) apoptosis after 24 h Aβ42O (1 μM) treatment, which was nearly completely blocked by SSH1 siRNA knockdown (Figures 6c and d), indicating that SSH1-dependent Cofilin activation is required for Aβ42O-induced apoptosis.
Aβ42O-induced ROS production, mitochondrial dysfunction, and apoptosis via the β1-integrin–SSH1–Cofilin activation pathway. (a and b) HT22 cells treated with vehicle or Aβ42O (1 μM) for 2 h with or without 1 h prior treatment with Nox inhibitor (VAS2870, 40 nM), HUTS-4 (β1-integrin allosteric activating IgG, 1 : 250), or MAB1965 (β1-integrin allosteric modulating IgG, 1 : 250) and subjected to live-cell imaging for JC-1 (mitochondrial membrane potential, green/red ratio), Mitosox-Red (mitochondrial superoxide indicator), or H2DCF (general ROS indicator). Note that β1-integrin conformational modulation or inhibition of Nox significantly reduces Aβ42O-induced mitochondrial dysfunction and overall ROS increase. Representative H2DCF images are shown in Supplementary Figure S6A. (b) Quantification of JC-1 green/red ratio, Mitosox-Red, and H2DCF intensities (n=6, 1-way ANOVA, post hoc Tukey, *P<0.05, **P<0.01, or #P<0.005 compared with Aβ42O. (c and d) HT22 cells transiently transfected with control or SSH1 siRNA, treated with / without Aβ42O (1 μM, 18 h) in 1% FBS medium, and subjected to FITC Annexin V/propidium iodide (PI) staining and fluorescence confocal microscopy. (c) Representative images showing reduction in Annexin V (early apoptosis) and PI (late apoptosis) staining in cells transfected with SSH1 siRNA (with Aβ42O). (d) Quantification of Annexin V/PI staining (n=4 replicates, ANOVA, post hoc Tukey, *P<0.05, **P<0.005, #P<0.0005). (e and f) Seven-month-old WT and APP/PS1 littermate mouse frontal cortex homogenates (1% Triton X-100) immunoprecipitated for pan-14-3-3 or SSH1 and immunoblotted for SSH1 or Cofilin. Same brain samples also directly immunoblotted for the indicated proteins. (e) Representative blots showing decreased 14-3-3/SSH1 complex and increased SSH1/Cofilin complex in APP/PS1 mice. (f) Quantification of SSH1/14-3-3 complex, Cofilin/SSH1 complex, p-Cofilin, and total Cofilin (n=4 mice/genotype, 2 M and 2 F, T-test, *P<0.02, **P<0.005)
A key mechanism of Cofilin regulation is via the binding of SSH1 to 14-3-3, which renders SSH1 sequestered in an inactive state. However, the oxidation of 14-3-3 releases SSH1, thereby leading to SSH1 activation.12, 30 In 7-month-old APP/PS1 mice, SSH1/Cofilin complexes and 14-3-3/SSH1 complexes were significantly increased and decreased, respectively, compared with WT littermate mice (Figures 6e and f), indicating the release of SSH1 from 14-3-3 and association of SSH1 with Cofilin in APP/PS1 mice. Accordingly, phospho-Cofilin was significantly decreased in APP/PS1 mice, despite no apparent changes in total 14-3-3, SSH1, or Cofilin in TX-100 solubilized extracts (Figures 6e and f). Aβ42O treatment also reduced 14-3-3/SSH1 complexes in HT22 cells, which was largely restored with prior treatment with MAB1965 or the potent anti-oxidant Trolox (Supplementary Figure S7B). Likewise, Aβ42O treatment significantly increased SSH1/Cofilin complexes in HT22 cells (Supplementary Figures S7C and D). These results therefore demonstrate that APP/Aβ promotes Cofilin activation at least in part via the β1-integrin-ROS-14-3-3/SSH1 pathway.
Cofilin reduction rescues app/aβ-induced gliosis and loss of synaptic proteins, as well as LTP and contextual memory deficits in APP/PS1 mice
We examined brains of 7-month-old APP/PS1, APP/PS1;Cofilin+/−, and WT littermate mice for neurodegenerative phenotypes, including glial fibrillary acidic protein (GFAP) for astrogliosis as well as PSD95 (postsynaptic) and Synapsin I (presynaptic) for synaptic integrity. As expected, APP/PS1 mouse hippocampi demonstrated significantly increased GFAP immunoreactivity throughout the hippocampus as well as diminished Synapsin I and PSD95 immunoreactivity within the stratum lucidium (synaptic terminating zone) of CA3 (Figures 7a and b). In contrast, APP/PS1;Cofilin+/− mice showed significantly reduced GFAP immunoreactivity and increased Synapsin I and PSD95 immunoreactivities compared with APP/PS1 littermate mice, essentially indistinguishable from WT littermates (Figures 7a and b).
Cofilin reduction rescues APP/Aβ-induced gliosis and loss of synaptic proteins as well as LTP and contextual memory deficits in APP/PS1 mice. (a and b) Seven-month-old WT, APP/PS1, and APP/PS1;Cofilin+/− mice immunostained for GFAP, Synapsin I, and PSD95. (a) Representative images showing that Cofilin reduction ameliorates astrogliosis and synaptic damage associated with APP/PS1 mice. (b–d) Quantification of mean PSD95 and Synapsin I intensities in the stratum lucidum (SL) (n=4 mice/genotype, 2 F and 2 M, ANOVA, post hoc Tukey, *P<0.05, #P<0.0005). (c–e) Stimulating electrode placed in the Schaffer collaterals of the hippocampus and recording glass electrode positioned at the CA1 stratum radiatum below the pyramidal cell layer. (c) Input/output analysis generated by step** up stimulation amplitude from 1 to 15mV in WT, APP/PS1, and APP/PS1;Cofilin+/− acute slices. No significant differences observed (n=24 slices from four mice, APP/PS1: 19 slices from four mice, APP/PS1;Cofilin+/−: n=20 slices from three mice). (d) PPF showing no significant differences across genotypes and interstimulus interval except between APP/PS1;Cofilin+/− and WT slices at the 40-ms interstimulus interval (two-way ANOVA, post hoc Bonferroni, *P<0.05; WT: n=32 slices from four mice, APP/PS1: n=31 slices from four mice, APP/PS1;Cofilin+/−: n=25 slices from three mice). (e) LTP induced by the TBS showing significant differences in fEPSP slope in APP/PS1 compared with WT and APP/PS1;Cofilin+/− slices (two-way ANOVA, post hoc Bonferroni, P<0.0001 at all time points). (WT: n=28 slices from four mice, APP/PS1: n=33 slices from four mice, APP/PS1;Cofilin+/−: n=20 slices from three mice). Error bars represent S.E.M. (f) Percentage of time spent freezing during training period on day 1 (no significant differences observed by one-way ANOVA or Kruskal–Wallis statistic; WT n=12, APP/PS1 n=8, APP/PS1;Cofilin+/− n=6; equal distribution of gender). Error bars represent S.E.M. (g) Percentage of time spend freezing during contextual fear conditioning (FC) on day 2 (Kruskal–Wallis statistic=9.66, P=0.008, genotypes=3, values=26; post hoc Dunn’s, *P<0.05; WT n=12, APP/PS1 n=8, APP/PS1;Cofilin+/− n=6; equalized distribution of gender). (h) Percentage of time spent freezing during cued fear conditioning (FC) freezing on day 2 (no significant differences observed by one-way ANOVA or Kruskal–Wallis statistic; WT n=12, APP/PS1 n=8, APP/PS1;Cofilin+/− n=6; equalized distribution of gender). (i) Total time spent on rotarod test (no significant differences observed by one-way ANOVA or Kruskal–Wallis statistic; WT n=11, APP/PS1 n=7, APP/PS1;Cofilin+/− n=5; equalized distribution of gender). (j) Total distance traveled during open-field test (no significant differences observed by one-way ANOVA or Kruskal–Wallis statistic; WT n=11, APP/PS1 n=7, APP/PS1;Cofilin+/− n=5; equalized distribution of gender). (k) Total time spent immobile during open-field test (no significant differences observed by 1-way ANOVA or Kruskal–Wallis statistic; WT n=11, APP/PS1 n=7, APP/PS1;Cofilin+/− n=5; equalized distribution of gender)
We next tested short-term and long-term synaptic plasticity from acute hippocampal slices prepared from 3-month-old WT, APP/PS1, and APP/PS1;Cofilin+/− mice. The stimulating electrode was placed in the Schaffer collaterals of the hippocampus, and the recording electrode was positioned at the CA1 stratum radiatum below the pyramidal cell layer. As shown in Figures 7c, the input–output curves did not markedly differ among WT, APP/PS1, and APP/PS1;Cofilin+/- slices. In paired pulse facilitation (PPF) experiments, we observed significant differences in fEPSP slope across genotypes among all interstimulus intervals (Figure 7d). However, correction for multiple comparisons showed that only APP/PS1;Cofilin+/− and WT slices differed significantly at the 40-ms interstimulus interval (Figure 7d). For LTP measurements, we detected no differences in fEPSP slope among WT, APP/PS1, and APP/PS1;Cofilin+/− slices at baseline (Figure 7e). However, after theta burst stimulation (TBS), we observed significant differences in fEPSP slope across genotypes for all time points (Figure 7e). Correction for multiple comparisons showed that APP/PS1 slices were significantly impaired in fEPSP slope compared with WT and APP/PS1;Cofliln+/− slices at every time point up to 1 h, indicating that Cofilin reduction rescues the deficits in LTP in APP/PS1 mice.
We carried out fear conditioning tests (contextual and cued), in which 7-month-old WT, APP/PS1, and APP/PS1;Cofilin+/− mice were trained on day 1 for both. On day 2, we tested mice for contextual and cued conditioning memory. We observed no significant differences between the genotypes in percent time spent freezing during the training phase (Figure 7f). However, we observed significant differences across genotypes in the percentage of time spent freezing during the hippocampus-dependent contextual fear conditioning test on day 2. Correction for multiple comparisons showed that WT and APP/PS1;Cofilin+/− mice significantly spend more time freezing than APP/PS1 mice (Figure 7g). On the hippocampus-independent cued fear conditioning test, we did not observe significant differences in the percentage of time spent freezing times across genotypes (Figure 7h). We also did not find significant differences among the three genotypes in the rotarod or open-field (total distance traveled and total time spent immobile) tests (Figures 7i–k), indicating the absence of salient perturbations in generalized motor activity or coordination. Taken together, these results demonstrate that endogenous Cofilin is required to mediate the APP/PS1-induced deficits in synaptic plasticity as well as hippocampus-dependent contextual memory but not cued memory.
Discussion
Molecular pathways that govern the production and neurotoxicity of Aβ are attractive therapeutic targets for AD. Although previous studies have shown Cofilin activation in AD brains and potential involvement of β1-integrin in Aβ-induced apoptosis,7, 8, 21, 22 it was unknown whether endogenous Cofilin per se and different β1-integrin conformers are required for molecular events leading to Aβ42O-induced neurodegeneration and how the β1-integrin–Cofilin signaling pathway mediates AD-relevant pathogenic processes.
In this study, we demonstrated for the first time that Aβ42O induces the depletion of surface β1-integrin via its direct binding to low-intermediate activation conformers of β1-integrin, as detected by competition of Aβ42O binding to neurons and HT22 cells with the β1-integrin activating antibody (HUTS-4) or MnCl2, both of which induce high conformational activation of β1-integrin.24, 26 Moreover, MnCl2 essentially eliminated Aβ42O binding to purified β1-integrin-Fc. However, Aβ42O did not bind to β1-integrin-Fc in the absence of Mg2+, suggesting that an intermediate/partially open conformation of integrin is required for binding. Although physiological ligands bind with high affinity to the highly active/open conformation of β1-integrin,26 the human Ecovirus binds to the relatively inactive/closed integrin conformer,31 similar to what we observed with Aβ42O. This finding raises the intriguing possibility of blocking Aβ42O-induced neurotoxic actions by conformational β1-integrin activation without compromising integrin function. In addition to preferentially binding to low-intermediate activation β1-integrin conformers, Aβ42O also increased the propensity of β1-integrin to assume a lower-activation conformation, probably by preventing bound β1-integrin from assuming a high-activation state. As Aβ42O reduced surface β1-integrin levels regardless of FN plating, Aβ42O likely does not compete with most physiological ligands (i.e., FN) for integrin binding, as seen by its preference for binding to lower-activation conformation of β1-integrin. Although we focused on β1-integrin in this study, it is well known that β1-integrin functions in concert with various α-integrin subunits, such as α2 and αv, which have been shown to be involved in Aβ neurotoxicity,21 as well as α6, which has been implicated in microglial phagocytosis of fibrillar Aβ together with β1.32
Our observation that the PrPc blocking antibody (6D11) significantly prevented Aβ42O-induced reduction in β1-integrin activation was somewhat surprising. However, it has been reported that PrPc and Pir-B, both of which bind Aβ42o, negatively regulate β1-integrin activation and signaling,33, 34 raising the possibility that loss of these receptors can also interfere with Aβ42O binding to β1-integrin in neurons. These receptors, including β1-integrin are typically clustered in pre- and postsynaptic membranes, and their activities are regulated by cross talk at multiple points of convergence by other transmembrane receptors. For example, PrPc-dependent activation of Fyn requires integrin engagement,35 and glutamate signaling via NMDARs and AMPARs depends on various Integrin heterodimers.16 Indeed, β1-integrin is also enriched in dendritic spines and is required for dendrite arborization, maintenance of synapses, and LTP.36, 37, 38, 39 In view of these observations, it is plausible that integrins operate physically and/or functionally in concert with other Aβ42O-binding receptors to mediate Aβ42O binding and neurotoxicity.
Deletion of β1-integrin resulted in the failure of Aβ42O to activate Cofilin. At the same time, Cofilin was also required for removal of surface β1-integrin, indicating that Cofilin normally has a role in the trafficking and/or internalization of β1-integrin. As such, we focused on β1-integrin and F-actin-associated structural focal components (Talin/Vinculin) and postsynaptic proteins known to function in concert with F-actin and synaptic remodeling, because the direct consequence of β1-integrin internalization is the disruption of the structural components of FCs (Talin and Vinculin), which anchor the cytoplasmic tail of β1-integrin to F-actin. Thus, it is likely that the F-actin severing activity of Cofilin is responsible for the removal of β1-integrin from the cell surface and the depletion of focal Talin/Vinculin by destabilizing or reducing the F-actin linkage to β1-integrin, changes which were directly analogous to F-actin per se and F-actin-regulated postsynaptic proteins (Drebrin and PSD95).
Cofilin activity is associated with dendritic spine growth and shrinkage during LTP and LTD, respectively,40, 41, 42 and Cofilin regulates the trafficking of AMPA receptors in dendritic spines.43 Therefore, Aβ42O-induced Cofilin activation and resultant F-actin severing/depolymerization also likely underlies the reduction in F-actin and synaptic proteins (PSD95 and Drebrin), both of which could be antagonized by Cofilin reduction or β1-integrin allosteric modulation. β-Arrestin 2 recruits Cofilin to dendritic spines upon NMDA receptor activation to control the remodeling of spines, and β-Arrestin 2 knockout neurons are resistant to Aβ-induced dendritic spine loss through spatial control of Cofilin activation.44 Likewise, Cofilin+/− neurons were resistant to Aβ-induced depletion of postsynaptic proteins. In view of these observations, it is plausible that Cofilin reduction prevents the sustained over-activation of Cofilin by Aβ oligomers to mitigate the loss of postsynaptic proteins and the deficits in LTP.
Our findings indicated that Aβ42O-induced and β1-dependent Cofilin activation, mitochondrial dysfunction, and apoptosis require endogenous SSH1 at least in part via ROS and 14-3-3. This is consistent with the induction of ROS production by NOX via Rac1-mediated signaling downstream of integrin,45 Aβ42O–induced Cofilin–Actin pathology via a NOX/PrPc-dependent manner,46 activation of SSH1 by oxidation of 14-3-3,12 Aβ-induced oxidation of 14-3-3,47, 48 and Cofilin-dependent mitochondrial dysfunction downstream of oxidative stress.13 Although a recent study reported that fibrillar Aβ42 can activate LIMK1 via p21-activated kinase 1, they also observed increased Cofilin dephosphorylation; therefore, Aβ oligomers and fibrils may impact the Cofilin activation pathway via similar but also divergent mechanisms.49 In addition to ROS-dependent activation of SSH1, it is likely that Aβ42O can also activate Cofilin via a mechanism involving an increase in cytosolic Ca2+, which in part may be mediated by the PrPc-mGluR5 complex,20 as Calcineurin dephosphorylates and activates SSH1.50 We have also shown that RanBP9, which activates Cofilin, also impairs mitochondrial Ca2+ buffering and mitochondrial homeostasis in a Cofilin-dependent manner.13, 51, 52
In summary, our findings indicate that a molecular pathway involving SSH1–Cofilin activation via direct engagement of lower-activation conformers of β1-integrin is essential for both Aβ42O-induced mitochondrial and synaptic dysfunction in AD. Therefore, promoting β1-integrin activation and/or inhibiting excessive Cofilin activation (i.e., SSH1 inhibition) represent potentially viable and novel therapeutic strategies to combat AD pathogenesis.
Materials and Methods
Cells, cDNA constructs, siRNA sequences, and transfections
Hippocampus-derived HT22 and CHO (Chinese Hamster Ovary) 7WD10 cells were maintained in DMEM containing 10% FBS. HT22 and CHO7WD10 cell lines were obtained from Professor David Schubert (Salk Institute, San Diego) and Professor Edward Koo (UC, San Diego). Green fluorescent protein–Vinculin construct was obtained from Professor Ballestrem (University of Manchester, UK).53 The β1-Fc integrin construct was obtained from Dr. Mould at the University of Manchester (UK). The β1-integrin-Fc construct encodes residues 1-708 (β1 extracellular region) fused in-frame to the hinge regions and CH2 and CH3 domains of human IgGγ1.26 RNAi sequences targeting Cofilin (5′-GGAGGACCUGGUGUUCAUC-3′) and SSH1 (5'-GAGGAGCUGUCCCGAUGAC-3') were obtained from GE Dharmacon (Lafayette, CO, USA). All cells were transfected for 48 h using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions with either cDNA expression constructs, empty vector controls, siRNA duplexes, or control single-stranded denatured control siRNAs before performing biochemical and/or immunocytochemical assays. All siRNAs were transfected at a final concentration of 100 nM. Cortical and hippocampal primary neurons were derived from postnatal day 0 (P0) pups and grown on Poly-d-lysine-coated coverslips or plates as previously described.51
Antibodies and reagents
Antibodies to APP (6E10, Covance, Princeton, NJ, USA), sAPPα (IBL-America, Minneapolis, MN, USA), sAPPβ (IBL-America), β1-integrin (M-106, Santa Cruz Biotechnology, Dallas, TX, USA), activated β1-integrin (HUTS-4, EMD Millipore, Billerica, MA, USA), allosteric β1-integrin neutralizing (MAB1965, EMD Millipore), 6D11 (Santa Cruz), Talin (H-300, Santa Cruz Biotechnology), Vinculin (hVIN-1, Sigma-Aldrich, St. Louis, MO, USA), Cofilin (D3F9, Cell Signaling, Danvers, MA, USA), phospho-Cofilin (77G2, Cell Signaling), SSH1 (SP1711, ECM Biosciences, Versailles, KY, USA), pan-14-3-3- (Santa Cruz Biotechnology), Actin (AC-74, Sigma-Aldrich), Tubulin (TU-02, Santa Cruz Biotechnology), Aβ (D5XD2, Cell Signaling), biotin (B7653, Sigma-Aldrich), GFAP (Invitrogen), Synapsin I (Invitrogen), PSD95 (Abcam, Cambridge, MA, USA), Drebrin (Abcam), MAP2 (EMD Millipore), HRP-linked secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA), and fluorescently labeled secondary antibodies (Invitrogen) were obtained from the indicated sources. The mouse monoclonal anti-RanBP9 antibody was a generous gift from Professor Elizabetta Bianchi (Pasteur Institute, France). Trolox (Cayman, Ann Arbor, MI, USA), JC-1 (Invitrogen), Mitosox-Red (Invitrogen), H2DCF (Invitrogen), NOX inhibitor III (EMD Millipore) were purchased from the indicated sources. Synthetic Aβ1-42 and FITC-Aβ1-42, and biotin-Aβ1-42 peptides were purchased from American Peptide (Sunnyvale, CA, USA). Aβ1-42 oligomers and fibrils were prepared precisely as previously characterized.23 Briefly, Aβ1-42 powder was dissolved in HFIP at 1 mM for 30 min at room temperature, aliquoted to Eppendorf tubes, allowed to evaporate overnight in fume hood, and subjected to speed vacuum for 1 h to remove traces of HFIP or moisture. To prepare Aβ oligomers, Aβ1-42 film was then dissolved in DMSO (5 mM), and F-12 cell culture medium (without phenol) was added to a final concentration of 100 μM Aβ1-42 and incubated at 4 °C for 24 h.
Cell/tissue lysis and immunoblotting
Cultured cells or brain homogenates were lysed with lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 2 mM EDTA, and 1% Triton X-100) unless stated otherwise. For separation of cytosolic versus focal adhesion-enriched (F) fractions, cytosolic proteins were first released with saponin buffer (0.1% saponin, 25 mM HEPES, and 75 mM potassium acetate) for 10 min on ice followed by extraction of remaining proteins by 2 × SDS sample buffer and sonication.54, Fear conditioning, open field, and rotarod behavior Fear conditioning (contextual and cued), rotarod, and open-field tasks were performed as previously described.59 For fear conditioning, an aversive stimulus (in this case a mild foot shock, 0.5 mA) was paired with an auditory conditioned stimulus (white noise) within a novel environment. Training consisted of two mild shocks paired with two conditioned stimuli with a 3-min interval between each shock. Freezing on the training day in response to the foot shock was used as an estimate of learning during the acquisition trial. To test conditioning to the context, animals were re-introduced to the same training chamber for 6 min and freezing behavior was recording by tracking software (Any-maze, Wood Dale, IL, USA) every second. To test conditioning to the tone, animals were introduced to a novel context, consisting of a chamber with different shape, floor, and olfactory cues from the training chamber. Mice were scored for 3 min, before and after the tone in the same manner described above. Learning was assessed by measuring freezing behavior (i.e., motionless position) every second. The open field was used as a standard test of general activity. Briefly, animals were monitored for 15 min in a 40-cm2 open field with a video tracking software (Any-maze). General activity levels were evaluated by measurements of total distance traveled and total time immobile. Motor performance was evaluated by an accelerating rotarod apparatus with a 3-cm diameter rod starting at an initial rotation of 4 r.p.m. slowly accelerating to 40 r.p.m over 5 min. The time spent on the rod during each of four trials per day for 2 consecutive days was measured previously described in Brownlow et al.60 Statistical data were analyzed by the GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA, USA) using Student’s t-test, one- or two-way ANOVA. One- or two-way ANOVA was followed by Tukey post hoc test. All quantitative graphs were expressed as mean±S.E.M. Differences were deemed significant when P<0.05.Statistical analysis and graphs
Change history
31 August 2022
A Correction to this paper has been published: https://doi.org/10.1038/s41418-022-01055-3
Abbreviations
- Aβ:
-
amyloid-β protein
- Aβ42O:
-
amyloid-β protein 1–42 oligomers
- AD:
-
Alzheimer’s disease
- APP:
-
amyloid precursor protein
- CHO cells:
-
Chinese Hamster Ovary cells
- DIV:
-
days in vitro
- F-actin:
-
filamentous actin
- FC:
-
focal complex
- fEPSP:
-
field excitatory postsynaptic potential
- FITC:
-
fluorescein isothiocyanate
- FN:
-
fibronectin
- GFAP:
-
glial fibrillary acidic protein
- H2DCF:
-
2′,7′-dichlorofluorescein
- IgG:
-
immunoglobulin G
- LTP:
-
long-term potentiation
- mGluR5:
-
metabotropic glutamate receptor 5
- mRFP:
-
monomeric red fluorescent protein
- LIMK1:
-
LIM kinase 1
- NOX:
-
NADPH oxidase
- PAK1:
-
p21-activated kinase 1
- Pir-B:
-
paired immunoglobin-like receptor-B
- PrPc:
-
Prion protein (cellular)
- PPF:
-
paired pulse facilitation
- PSD95:
-
postsynaptic density-95
- ROS:
-
reactive oxygen species
- SSH1:
-
Slingshot homolog 1
- TfR:
-
transferrin receptor
References
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535–539.
Selkoe DJ . Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192: 106–113.
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL . Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866–2875.
Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP et al. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 2006; 9: 234–242.
Moreira PI, Santos MS, Moreno A, Oliveira C . Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep 2001; 21: 789–800.
Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS . Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 2010; 107: 18670–18675.
Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg JR . Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Nat Cell Biol 2000; 2: 628–636.
Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC et al. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 2013; 341: 1399–1404.
Bernstein BW, Bamburg JR . ADF/cofilin: a functional node in cell biology. Trends Cell Biol 2010; 20: 187–195.
Niwa R, Nagata-Ohashi K, Takeichi M, Mizuno K, Uemura T . Control of actin reorganization by Slingshot, a family of phosphatases that dephosphorylate ADF/cofilin. Cell 2002; 108: 233–246.
Kurita S, Watanabe Y, Gunji E, Ohashi K, Mizuno K . Molecular dissection of the mechanisms of substrate recognition and F-actin-mediated activation of cofilin-phosphatase Slingshot-1. J Biol Chem 2008; 283: 32542–32552.
Kim JS, Huang TY, Bokoch GM . Reactive oxygen species regulate a slingshot-cofilin activation pathway. Mol Biol Cell 2009; 20: 2650–2660.
Roh SE, Woo JA, Lakshmana MK, Uhlar C, Ankala V, Boggess T et al. Mitochondrial dysfunction and calcium deregulation by the RanBP9-cofilin pathway. FASEB J 2013; 27: 4776–4789.
Klamt F, Zdanov S, Levine RL, Pariser A, Zhang Y, Zhang B et al. Oxidant-induced apoptosis is mediated by oxidation of the actin-regulatory protein cofilin. Nat Cell Biol 2009; 11: 1241–1246.
Bernstein BW, Shaw AE, Minamide LS, Pak CW, Bamburg JR . Incorporation of cofilin into rods depends on disulfide intermolecular bonds: implications for actin regulation and neurodegenerative disease. J Neurosci 2012; 32: 6670–6681.
Becchetti A, Pillozzi S, Morini R, Nesti E, Arcangeli A . New insights into the regulation of ion channels by integrins. Int Rev Cell Mol Biol 2010; 279: 135–190.
Zamir E, Geiger B . Molecular complexity and dynamics of cell-matrix adhesions. J Cell Sci 2001; 114: 3583–3590.
Kim C, Ye F, Ginsberg MH . Regulation of integrin activation. Annu Rev Cell Dev Biol 2011; 27: 321–345.
Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM . Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457: 1128–1132.
Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 2013; 79: 887–902.
Wright S, Malinin NL, Powell KA, Yednock T, Rydel RE, Griswold-Prenner I . Alpha2beta1 and alphaVbeta1 integrin signaling pathways mediate amyloid-beta-induced neurotoxicity. Neurobiol Aging 2007; 28: 226–237.
Wang Q, Klyubin I, Wright S, Griswold-Prenner I, Rowan MJ, Anwyl R . Alpha v integrins mediate beta-amyloid induced inhibition of long-term potentiation. Neurobiol Aging 2008; 29: 1485–1493.
Dahlgren KN, Manelli AM, Stine WB Jr ., Baker LK, Krafft GA, LaDu MJ . Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046–32053.
Luque A, Gomez M, Puzon W, Takada Y, Sanchez-Madrid F, Cabanas C . Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem 1996; 271: 11067–11075.
Aljamal-Naylor R, Wilson L, McIntyre S, Rossi F, Harrison B, Marsden M et al. Allosteric modulation of beta1 integrin function induces lung tissue repair. Adv Pharmacol Sci 2012; 2012: 768720.
Valdramidou D, Humphries MJ, Mould AP . Distinct roles of beta1 metal ion-dependent adhesion site (MIDAS), adjacent to MIDAS (ADMIDAS), and ligand-associated metal-binding site (LIMBS) cation-binding sites in ligand recognition by integrin alpha2beta1. J Biol Chem 2008; 283: 32704–32714.
Raghavan S, Bauer C, Mundschau G, Li Q, Fuchs E . Conditional ablation of beta1 integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination. J Cell Biol 2000; 150: 1149–1160.
Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004; 13: 159–170.
Shirao T, Gonzalez-Billault C . Actin filaments and microtubules in dendritic spines. J Neurochem 2013; 126: 155–164.
Eiseler T, Doppler H, Yan IK, Kitatani K, Mizuno K, Storz P . Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. Nat Cell Biol 2009; 11: 545–556.
Jokinen J, White DJ, Salmela M, Huhtala M, Kapyla J, Sipila K et al. Molecular mechanism of alpha2beta1 integrin interaction with human echovirus 1. EMBO J 2010; 29: 196–208.
Koenigsknecht J, Landreth G . Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci 2004; 24: 9838–9846.
Pereira S, Zhang H, Takai T, Lowell CA . The inhibitory receptor PIR-B negatively regulates neutrophil and macrophage integrin signaling. J Immunol 2004; 173: 5757–5765.
Loubet D, Dakowski C, Pietri M, Pradines E, Bernard S, Callebert J et al. Neuritogenesis: the prion protein controls beta1 integrin signaling activity. FASEB J 2012; 26: 678–690.
Pantera B, Bini C, Cirri P, Paoli P, Camici G, Manao G et al. PrPc activation induces neurite outgrowth and differentiation in PC12 cells: role for caveolin-1 in the signal transduction pathway. J Neurochem 2009; 110: 194–207.
Warren MS, Bradley WD, Gourley SL, Lin YC, Simpson MA, Reichardt LF et al. Integrin beta1 signals through Arg to regulate postnatal dendritic arborization, synapse density, and behavior. J Neurosci 2012; 32: 2824–2834.
Babayan AH, Kramar EA, Barrett RM, Jafari M, Haettig J, Chen LY et al. Integrin dynamics produce a delayed stage of long-term potentiation and memory consolidation. J Neurosci 2012; 32: 12854–12861.
Chan CS, Weeber EJ, Kurup S, Sweatt JD, Davis RL . Integrin requirement for hippocampal synaptic plasticity and spatial memory. J Neurosci 2003; 23: 7107–7116.
Bernard-Trifilo JA, Kramar EA, Torp R, Lin CY, Pineda EA, Lynch G et al. Integrin signaling cascades are operational in adult hippocampal synapses and modulate NMDA receptor physiology. J Neurochem 2005; 93: 834–849.
Rex CS, Chen LY, Sharma A, Liu J, Babayan AH, Gall CM et al. Different Rho GTPase-dependent signaling pathways initiate sequential steps in the consolidation of long-term potentiation. J Cell Biol 2009; 186: 85–97.
Zhou Q, Homma KJ, Poo MM . Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 2004; 44: 749–757.
Chen LY, Rex CS, Casale MS, Gall CM, Lynch G . Changes in synaptic morphology accompany actin signaling during LTP. J Neurosci 2007; 27: 5363–5372.
Gu J, Lee CW, Fan Y, Komlos D, Tang X, Sun C et al. ADF/cofilin-mediated actin dynamics regulate AMPA receptor trafficking during synaptic plasticity. Nat Neurosci 2010; 13: 1208–1215.
Pontrello CG, Sun MY, Lin A, Fiacco TA, DeFea KA, Ethell IM . Cofilin under control of beta-arrestin-2 in NMDA-dependent dendritic spine plasticity, long-term depression (LTD), and learning. Proc Natl Acad Sci USA 2012; 109: E442–E451.
Werner E, Werb Z . Integrins engage mitochondrial function for signal transduction by a mechanism dependent on Rho GTPases. J Cell Biol 2002; 158: 357–368.
Walsh KP, Minamide LS, Kane SJ, Shaw AE, Brown DR, Pulford B et al. Amyloid-beta and proinflammatory cytokines utilize a prion protein-dependent pathway to activate NADPH oxidase and induce cofilin-actin rods in hippocampal neurons. PloS One 2014; 9: e95995.
Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G et al. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 2005; 132: 313–324.
Sultana R, Newman SF, Abdul HM, Cai J, Pierce WM, Klein JB et al. Protective effect of D609 against amyloid-beta1-42-induced oxidative modification of neuronal proteins: redox proteomics study. J Neurosci Res 2006; 84: 409–417.
Mendoza-Naranjo A, Contreras-Vallejos E, Henriquez DR, Otth C, Bamburg JR, Maccioni RB et al. Fibrillar amyloid-beta1-42 modifies actin organization affecting the cofilin phosphorylation state: a role for Rac1/cdc42 effector proteins and the slingshot phosphatase. J Alzheimer's Dis 2012; 29: 63–77.
Wang Y, Shibasaki F, Mizuno K . Calcium signal-induced cofilin dephosphorylation is mediated by Slingshot via calcineurin. J Biol Chem 2005; 280: 12683–12689.
Woo JA, Jung AR, Lakshmana MK, Bedrossian A, Lim Y, Bu JH et al. Pivotal role of the RanBP9-cofilin pathway in Abeta-induced apoptosis and neurodegeneration. Cell Death Differ 2012; 19: 1413–1423.
Liu T, Roh SE, Woo JA, Ryu H, Kang DE . Cooperative role of RanBP9 and P73 in mitochondria-mediated apoptosis. Cell Death Dis 2013; 4: e476.
Humphries JD, Wang P, Streuli C, Geiger B, Humphries MJ, Ballestrem C . Vinculin controls focal adhesion formation by direct interactions with talin and actin. J Cell Biol 2007; 179: 1043–1057.
Soriano S, Kang DE, Fu M, Pestell R, Chevallier N, Zheng H et al. Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J Cell Biol 2001; 152: 785–794.
Kang DE, Soriano S, **a X, Eberhart CG, De SB, Zheng H et al. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell 2002; 110: 751–762.
Lakshmana MK, Yoon IS, Chen E, Bianchi E, Koo EH, Kang DE . Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation. J Biol Chem 2009; 284: 11863–11872.
Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE et al. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods 2010; 194: 144–153.
Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem 2002; 277: 39944–39952.
Bolognani F, Qiu S, Tanner DC, Paik J, Perrone-Bizzozero NI, Weeber EJ . Associative and spatial learning and memory deficits in transgenic mice overexpressing the RNA-binding protein HuD. Neurobiol Learn Mem 2007; 87: 635–643.
Brownlow ML, Benner L, D'Agostino D, Gordon MN, Morgan D . Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. PloS One 2013; 8: e75713.
Acknowledgements
This work was supported in part by NIH/NIA (1R01AG033055, DEK), NIH/NIA (1K02AG031920, DEK), and Florida Department of Health (5AZ07, DEK). We thank Dr. Elizabetta Bianchi for providing the RanBP9 monoclonal antibody.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Edited by N Bazan
Supplementary Information accompanies this paper on Cell Death and Differentiation website
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
About this article
Cite this article
Woo, J., Zhao, X., Khan, H. et al. Slingshot-Cofilin activation mediates mitochondrial and synaptic dysfunction via Aβ ligation to β1-integrin conformers. Cell Death Differ 22, 921–934 (2015). https://doi.org/10.1038/cdd.2015.5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cdd.2015.5
- Springer Nature Limited
This article is cited by
-
Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis
Acta Pharmacologica Sinica (2022)
-
Decreased circadian fluctuation in cognitive behaviors and synaptic plasticity in APP/PS1 transgenic mice
Metabolic Brain Disease (2020)
-
Early Synaptic Alterations and Selective Adhesion Signaling in Hippocampal Dendritic Zones Following Organophosphate Exposure
Scientific Reports (2019)
-
The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis?
Acta Neuropathologica (2019)
-
Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity
Nature Communications (2017)